| GTO ID | GTC4013 |
| Trial ID | NCT02636036 |
| Disease | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma |
| Altered gene | E1A|E1B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | ColoAd1|Enadenotucirev |
| Co-treatment | Nivolumab/Ipilimumab |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors |
| Year | 2016 |
| Country | United States |
| Company sponsor | Akamis Bio |
| Other ID(s) | ColoAd1-1003 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||
|
|||||||||